Venus Medtech Executive Director Resigns, Board Signals Smooth Transition

Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ) has issued an announcement.

Venus Medtech (Hangzhou) Inc., a Hong Kong-listed Chinese medical technology company specializing in cardiovascular devices, is governed by a board that includes executive, non-executive and independent non-executive directors. This structure underpins its regulatory obligations and strategic oversight as it operates within the expanding healthcare and medtech markets in China and abroad.

The company announced that executive director Mr. Liqiao Ma resigned from the board and all positions within the group on May 15, 2026, citing personal commitments and confirming no disagreement with the board. The departure, which the company states raises no issues requiring attention from the exchange or stakeholders, represents a change in senior leadership but is framed as a routine governance development rather than a sign of internal conflict or operational disruption.

More about Venus Medtech (Hangzhou), Inc. Class H

Venus Medtech (Hangzhou) Inc. is a Hong Kong-listed medical technology company focused on developing and commercializing cardiovascular devices in mainland China and international markets. The group operates through a board comprising executive, non-executive and independent non-executive directors, reflecting a typical governance structure for a PRC-incorporated, Hong Kong-traded medtech issuer.

The company’s leadership mix, including executive and independent directors, supports its strategy and regulatory compliance in the competitive medical device sector. Its listing on the Stock Exchange of Hong Kong provides access to global capital, while its PRC base anchors it in one of the world’s fastest-growing healthcare markets.

Average Trading Volume: 1,173,553

Technical Sentiment Signal: Sell

Current Market Cap: HK$701.2M

See more insights into 2500 stock on TipRanks’ Stock Analysis page.